scholarly journals Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs

2018 ◽  
Vol 13 (1) ◽  
pp. 1435124 ◽  
Author(s):  
Ghada El Sagheer ◽  
Elwy Soliman ◽  
Asmaa Ahmad ◽  
Lamiaa Hamdy
2016 ◽  
Vol 28 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Mohamed A.S. Kohla ◽  
Hala El-Said ◽  
Ashraf El-Fert ◽  
Nermine Ehsan ◽  
Sameera Ezzat ◽  
...  

Cells ◽  
2018 ◽  
Vol 7 (11) ◽  
pp. 185
Author(s):  
Salwa Abo El-khair ◽  
Mona Arafa ◽  
Tarek Besheer ◽  
Ahmed El-Eraky ◽  
Ayman Elsamanoudy

Chronic hepatitis C is implicated in insulin resistance (IR) susceptibility. An X-ray repair cross-complementing group 1 gene (XRCC1) is proposed to be a candidate gene for a study of IR susceptibility. So, this study aims to investigate the possible association of the XRCC1 gene polymorphisms with the risk of IR related to chronic hepatitis C virus (HCV) infection in Egyptian patients. In a case-control study, a total of 210 subjects, including 140 chronic HCV patients (87 patients with IR and 53 without IR) and 70 healthy controls, were included. Two genetic polymorphisms (c.1254C > T and c.1517G > C) of the XRCC1 gene were genotyped via the PCR-restriction fragment length polymorphism (PCR-RFLP) technique. The result of the current study revealed that these two single nucleotide polymorphisms (SNPs) have statistically significant influences on susceptibility to IR in chronic HCV infected Egyptian patients. It could be concluded that c.1254C > T, the TT genotype, CT/CC carriers as well as c.1517G > C, the CC genotype and GC/GG carriers might be associated with increased IR susceptibility. Moreover, T-allele of c.1254C > T and the C-allele of c.1517G > C genetic variants might influence the susceptibility.


2011 ◽  
Vol 8 (1) ◽  
Author(s):  
Amal A Mohamed ◽  
Samah A Loutfy ◽  
James D Craik ◽  
Abdel Gawad M Hashem ◽  
Ibrahem Siam

2006 ◽  
Vol 13 (1) ◽  
pp. 11-15 ◽  
Author(s):  
Gamal Badra ◽  
Imam Waked ◽  
Carlo Selmi ◽  
Saleh M. Saleh ◽  
Ahmed El-Shaarawy ◽  
...  

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 naïve Egyptian patients (38 males, 32 ± 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5%) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.


Sign in / Sign up

Export Citation Format

Share Document